![]() |
![]()
|
New Pharmaxis Board Appointment24 June 2008 - Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced the appointment of senior Australian pharmaceutical executive Will Delaat to its board of directors.Mr Delaat has 35 years experience in the global pharmaceutical industry, most recently as the managing director of the Australian subsidiary of Merck & Co., a position he held from 1997 until his recent retirement. During his career Mr Delaat has held executive positions in both Europe and Australia for Merck and AstraZeneca. Mr Delaat is experienced in sales and marketing and has been responsible for international product launches and commercialisation of respiratory products. Mr Delaat also serves the pharmaceutical industry in important representative roles. He is chairman of the Australian pharmaceutical industry's peak body, Medicines Australia, and is chairman of the Pharmaceuticals Industry Council. "Will Delaat is one of Australia's pharmaceutical industry leaders" said Pharmaxis Chairman, Denis Hanley. "The Pharmaxis board will benefit from his invaluable skills and experience."
In accepting the board director position Mr Delaat said: "Pharmaxis holds
enormous promise and I look forward to being part of its effort to bring
innovative medicines to patients world-wide."
|
![]() |
|||